What's Hot

    SHEIN TO PRESENT FALL/WINTER 2023 COLLECTIONS THROUGH LIVESTREAM FASHION SHOW, SHEIN LIVE: FRONT ROW

    September 22, 2023

    Huawei Connect TECH4ALL Summit Explores How Technology and Partnerships Enable Inclusion and Sustainability

    September 22, 2023

    Huawei’s Xinghe Network Accelerates Industry Intelligence

    September 22, 2023
    Iran DispatchIran Dispatch
    • Automotive
    • Business
    • Entertainment
    • Health
    • Lifestyle
    • Luxury
    • News
    • More
      • Sports
      • Technology
      • Travel
    Iran DispatchIran Dispatch
    Home » Early results of a study on an Alzheimer’s drug show promise
    Health

    Early results of a study on an Alzheimer’s drug show promise

    September 30, 2022
    Facebook Twitter Pinterest LinkedIn Tumblr Email

    The shares of Biogen and other drugmakers researching Alzheimer’s disease surged Wednesday after Japan’s Eisai Co. Ltd.. reported its potential treatment appeared to slow the disease in a late-stage study. Lecanemab, the drugmaker’s treatment, reduced patients’ clinical decline by 27% after 18 months of infused treatment compared to placebos or fake drugs, according to AP reports.

    Early results of a study on an Alzheimer's drug show promiseThe results of Eisai’s global study of nearly 1,800 people with early-stage Alzheimer’s were announced late Tuesday. Mental decline and ability to do daily activities such as dressing and eating were measured using a scale. Eisai Co. Ltd. said it would present full research results at a conference in late November. The findings will also be published in a peer-reviewed medical journal.

    The company is already seeking an accelerated approval from the U.S. Food and Drug Administration, and the agency is expected to decide by early next year. Biogen and Eisai will jointly promote the drug. Researchers usually caution against evaluating a study before full results are released. According to Mizuho Securities analyst Graig Suvannavejh, the initial findings are “quite robust” and support regulatory approval.

    According to the Alzheimer’s Association, the findings provide the highest hope so far for treating the disease’s underlying causes. Alzheimer’s disease affects some 6 million Americans and many more worldwide, gradually destroying parts of the brain that control memory, reasoning, communication, and basic daily functions.

    There is no known cure for Alzheimer’s disease. Researchers are still trying to understand what causes the disease, and long-standing treatments only manage symptoms. It has been nearly two decades since Biogen introduced a new Alzheimer’s drug. However, it has generally flopped after debuting at $56,000 annually, which Biogen later reduced. Due to weak evidence that the drug slows Alzheimer’s progression, doctors have been hesitant to prescribe it. Due to the drug’s high price and uncertain benefits, insurers have blocked or restricted coverage.

    Related Posts

    New research warns of liver risk from daily soda consumption

    September 6, 2023

    Sheesha cafes are a lethal mix of health risks and idle talk

    September 6, 2023

    Blue Zone centenarians’ longevity linked to high-carb diet

    September 1, 2023

    Cholesterol – the silent killer and Its Impact on hearing

    August 29, 2023
    Latest News

    From India to Brazil, leadership transition marks G20 Summit’s conclusion

    September 11, 2023

    African Union Inducted into G20 on India’s Initiative

    September 9, 2023

    Biden and Modi cement ties as India ascends global stage

    September 9, 2023

    UN calls for greater female representation in police forces worldwide

    September 8, 2023

    Digital work revolution sees the world’s gig economy expand by 12 percent

    September 8, 2023

    AI drives MENA Newswire’s entry into Saudi digital media

    September 8, 2023

    ASEAN Summit in Jakarta sees PM Modi advocating India’s growing global impact

    September 7, 2023

    Air Canada faces backlash as passengers evicted for refusing vomit-soaked seating

    September 7, 2023
    © 2022 Iran Dispatch | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.